Filing Details
- Accession Number:
- 0001209191-21-027939
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-22 16:04:14
- Reporting Period:
- 2021-04-21
- Accepted Time:
- 2021-04-22 16:04:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1708493 | Harpoon Therapeutics Inc. | HARP | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1134655 | Ansbert Gadicke | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1687078 | Mpm Oncology Impact Management Lp | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1691428 | L.p. Fund Impact Oncology Ubs | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1721035 | Mpm Oncology Impact Management Gp Llc | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No | |
1721036 | L.p. Management (Cayman) Fund Impact Oncology | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-04-21 | 8,417 | $18.94 | 7,020,675 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2021-04-21 | 555 | $19.48 | 7,020,120 | No | 4 | S | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
Footnotes
- Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.
- The shares were sold as follows: 7,398 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,019 by MPM Asset Management LLC ("AM LLC").
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $19.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 309,264 by AM LLC and 3,805,468 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- The shares were sold as follows: 488 by UBS Oncology and 67 by AM LLC.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.40 to $19.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 309,197 by AM LLC and 3,804,980 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.